Principal Investigator

Scot C
Awardee Organization

United States

Fiscal Year
Activity Code
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

MaineHealth Cancer Care Network (MHCCN) and NCORP Activities across the Lifespan

Maine ranks 12th and 8th in adult cancer incidence and mortality respectively, and pediatric cancer incidence rates are the third highest in the nation, contributing to marked cancer health disparities in our state. In 2018, it is estimated there will be 8,600 new adult cancer cases diagnosed in Maine; cancer is the most common cause of death in our state. Of these adult cases, 6,185 (72%) will receive their care at a MaineHealth Cancer Care Network (MHCCN) hospital or outpatient facility. This patient volume is akin to any major metropolitan cancer center. With only 1.3 million residents, Maine is a small state, is the most rural state, and has the oldest population in the nation. There are significant cancer risk behaviors and exposures, and there are numerous socioeconomic and geographic challenges as well, further compounding our cancer burden. The MHCCN is clearly organized around patient, health provider, and healthcare system multi-tiered strategies and interventions that are prioritized in the NCORP solicitation and defended in this proposal. Our health system embarked upon a comprehensive oncology strategic planning process in 2014 that in a relatively short period has led to the opportunity to submit our response to this FOA. Consensus was reached on the model of cancer care that we would pursue. The singular goal is to ensure that "the right care, in the right location, as close to home as possible" will be provided. Cancer patients in our state and their families desire access to state-of-the-art patient-centered care. This NCORP application could not come at a more auspicious time for our organization, coinciding with significant growth and substantive multimillion dollar investment in MH Oncology over the past couple years. With this backdrop, the fundamental goal of our application is to commit and contribute to a robust slate of NCORP activities across the lifespan including pediatric, adolescent and young adults, adults, and elderly cancer patients in our communities and rural care settings. We have assembled a highly interactive and interdisciplinary team across our network to participate in and lead this research endeavor. Our central hypothesis is that developing a highly interactive and interdisciplinary approach to cancer care that is at all times patient-centered throughout MH Oncology will have salutary effects on all aspects of our cancer care across the continuum of prevention, screening, diagnosis, treatment, survivorship, end-of-life, and care delivery not only for our patients and their families but for other aspects critical to our mission – including educating the next generation of healthcare providers and expanding our research pursuits especially in rural areas within our care network. We propose 4 aims: To conduct and actively participate in 1) cancer control research, 2) cancer prevention research, and 3) cancer care delivery research studies; and 4) to capitalize upon clinical research opportunities afforded by NCORP and our newly awarded Northern New England Clinical and Translational Research Network grant (1U54 GM115517). We will pursue these aims across the lifespan engaging both children and adults. The MHCNN has every expectation that will we make substantive contributions across the spectrum of the NCORP research portfolio. We will capitalize on our institutional assets, patient resources, and expertise from the vantage point of community and rural settings to add value across the lifespan and provide leadership to the NCORP. We welcome and value the opportunity to join the NCORP network as a new institutional member.


  • Wenzel L, Huang HQ, Cella D, McKinney CO, Zevon MA, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, von Gruenigen VE. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. Gynecologic oncology. 2021 Nov;163(2):392-397. Epub 2021 Sep 20. PMID: 34548162
  • Weiss AR, Chen YL, Scharschmidt TJ, Chi YY, Tian J, Black JO, Davis JL, Fanburg-Smith JC, Zambrano E, Anderson J, Arens R, Binitie O, Choy E, Davis JW, Hayes-Jordan A, Kao SC, Kayton ML, Kessel S, Lim R, Meyer WH, Million L, Okuno SH, Ostrenga A, Parisi MT, Pryma DA, Randall RL, Rosen MA, Schlapkohl M, Shulkin BL, Smith EA, Sorger JI, Terezakis S, Hawkins DS, Spunt SL, Wang D. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. The Lancet. Oncology. 2020 Aug;21(8):1110-1122. Epub 2020 Jul 20. PMID: 32702309
  • Alvarez E, He J, Spunt SL, Hayes-Jordan A, Kao SC, Parham DM, Million L, Weiss AR, Barkauskas DA. Lymph node metastases in paediatric and young adult patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Findings from Children's Oncology Group (COG) study ARST0332. European journal of cancer (Oxford, England : 1990). 2023 Feb;180:89-98. Epub 2022 Nov 25. PMID: 36566574
  • Haduong JH, Heske CM, Allen-Rhoades W, Xue W, Teot LA, Rodeberg DA, Donaldson SS, Weiss A, Hawkins DS, Venkatramani R. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatric blood & cancer. 2022 Apr;69(4):e29511. Epub 2022 Feb 7. PMID: 35129294
  • Gartrell J, Panetta JC, Baker SD, Chen YL, Hawkins DS, Ostrenga A, Scharschmidt TJ, Spunt SL, Wang D, Weiss AR. The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children's Oncology Group and NRG Oncology study ARST1321. Cancer chemotherapy and pharmacology. 2022 Apr;89(4):551-557. Epub 2022 Jan 27. PMID: 35083502
  • Hsu IC, Rodgers JP, Shinohara K, Purdy J, Michalski J, Roach M 3rd, Vigneault E, Ivker RA, Pryzant RM, Kuettel M, Taussky D, Gustafson GS, Raben A, Sandler HM. Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate. International journal of radiation oncology, biology, physics. 2021 Jul 1;110(3):700-707. Epub 2020 Nov 10. PMID: 33186617
  • Kayton ML, Weiss AR, Xue W, Binitie O, Hayes Dixon A, Randall RL, Sorger JI, Hawkins DS, Spunt SL, Wang D, Million L, Terezakis S, Choy E, Okuno SH, Venkatramani R, Chen YL, Scharschmidt TJ. Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG Oncology. Journal of surgical oncology. 2023 Apr;127(5):871-881. Epub 2023 Feb 13. PMID: 36779385
  • Mai PL, Huang HQ, Wenzel LB, Han PK, Moser RP, Rodriguez GC, Boggess J, Rutherford TJ, Cohn DE, Kauff ND, Phillips KA, Wilkinson K, Wenham RM, Hamilton C, Powell MA, Walker JL, Greene MH, Hensley ML. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecologic oncology. 2020 Jan;156(1):131-139. Epub 2019 Nov 21. PMID: 31759774
  • McNeer JL, Devidas M, Dai Y, Carroll AJ, Heerema NA, Gastier-Foster JM, Kahwash SB, Borowitz MJ, Wood BL, Larsen E, Maloney KW, Mattano L, Winick NJ, Schultz KR, Hunger SP, Carroll WL, Loh ML, Raetz EA. Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Apr 1;37(10):780-789. Epub 2019 Feb 11. PMID: 30742559